Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Can we afford the cost of newly approved targeted therapeutics in the management of breast cancer globally?

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC